The approval of the IDH1 inhibitor was based on CR/CRh rates of 42.9% observed in a Phase I dose escalation/expansion study of 258 patients, including 34 patients with untreated AML (Roboz et al., 2018). Here, IDH1 is linked to acute myeloid leukemia.